PharmAla Biotech Logo 800 x 422.png
PharmAla named an Intellectual Property Ontario Client
February 22, 2024 08:55 ET | PharmAla Biotech
PharmAla recieves a non-dilutive grant from IP Ontario (IPON) to support its patent work in international markets.
PharmAla Biotech Logo 800 x 422.png
PharmAla Data to be Published in ACS Chemical Neuroscience
February 20, 2024 08:55 ET | PharmAla Biotech
PharmAla's drug discovery data to be published in ACS Chemical Neuroscience; PharmAla presents data at ISRP Conference in New Orleans
PharmAla Biotech Logo 800 x 422.png
PharmAla and Red Light Holland to Collaborate on Medical Psilocybin Development
February 09, 2024 08:10 ET | PharmAla Biotech
PharmAla signs all-cash agreement to consult for Red Light Holland
PharmAla Biotech Logo 800 x 422.png
PharmAla releases Profitable Q1 Interim Financial Statement and Business Update
January 31, 2024 10:58 ET | PharmAla Biotech
PharmAla releases Profitable Q1 Interim Financial Statement, and will host investor webinar to discuss prominent changes to the business & FDA timelines
PharmAla Biotech Logo 800 x 422.png
PharmAla granted a Controlled Drugs & Substances Dealer’s License by Health Canada
January 25, 2024 12:09 ET | PharmAla Biotech
PharmAla granted a Health Canada Controlled Drugs and Substances Dealer's License
PharmAla Biotech Logo 800 x 422.png
PharmAla receives new “MDXXF” ticker from FINRA for OTCQB Listing
January 24, 2024 09:35 ET | PharmAla Biotech
PharmAla recieved a new OTCQB ticker, MDXXF.
PharmAla Biotech Logo 800 x 422.png
PharmAla-1 Molecule Receives US Patent Prosecution Highway Acceptance
January 08, 2024 08:55 ET | PharmAla Biotech
PharmAla announces that its novel P1 molecule has been accepted by USPTO to its accelerated "Patent Prosecution Highway"
PharmAla Biotech Logo 800 x 422.png
PharmAla Files Audited Financials for Year Ending August 31, 2023
December 29, 2023 16:00 ET | PharmAla Biotech
PharmAla releases audited year-end financials for the period ended August 31st.
PharmAla Biotech Logo 800 x 422.png
PharmAla Biotech and Filament Health Announce Release of Second Batch of GMP MDMA Capsules
November 15, 2023 08:55 ET | PharmAla Biotech
PharmAla Biotech contracted with Filament Health to manufacture a second batch of MDMA capsules; manufacturing is complete and shipped to clients.
PharmAla Biotech Logo 800 x 422.png
World’s First Observational Trial to Assess Real-World Efficacy of MDMA Treatment
November 09, 2023 08:55 ET | PharmAla Biotech
PharmAla partners with Heroic Hearts Canada and the University of Calgary to launch the world's first observational rial into MDMA's real-world efficacy